FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059094471> ?p ?o ?g. }

• W2059094471 endingPage "1887" @default.
• W2059094471 startingPage "1882" @default.
• W2059094471 abstract "No AccessJournal of UrologyAdult Urology1 Nov 2010Radio Frequency Ablation of Renal Tumors in Patients With Metastatic Renal Cell Carcinoma Jose A. Karam, Kamran Ahrar, Christopher G. Wood, Eric Jonasch, Raghunandan Vikram, Claudio Romero, Nizar Tannir, and Surena F. Matin Jose A. KaramJose A. Karam Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Kamran AhrarKamran Ahrar Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Christopher G. WoodChristopher G. Wood Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Eric JonaschEric Jonasch Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with Pfizer, Novartis, Bayer Onyx, Wyeth and Genentech. More articles by this author , Raghunandan VikramRaghunandan Vikram Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Claudio RomeroClaudio Romero Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Nizar TannirNizar Tannir Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , and Surena F. MatinSurena F. Matin Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.06.109AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We retrospectively evaluated the feasibility, safety and outcomes of radio frequency ablation of primary renal tumors to control local disease while preserving renal parenchyma in a series of patients with metastatic renal cell carcinoma in a single institutional, multidisciplinary setting. Materials and Methods: We evaluated the records of patients with metastatic renal cell carcinoma who underwent percutaneous radio frequency ablation of a primary renal tumor. Patient demographic and disease characteristics, adjunctive medical and surgical therapies, recurrence and clinical outcomes were studied. Results: A total of 15 patients treated between 2002 and 2008 met study inclusion criteria. There was no incomplete ablation or local recurrence. Ten patients had biopsy proven renal cell carcinoma in the ablated renal mass. Eight patients had a solitary metastasis, 3 had metastasis at 2 sites and 4 had 3 or more metastatic sites. Four patients experienced major complications. Median radiographic and clinical followup in patients at risk for an event was 25.5 and 33.0 months, respectively. The overall survival rate 1, 3 and 5 years after radio frequency ablation was 73.3%, 57.1% and 38.1%, respectively. At last evaluation 4 patients were in complete remission, 4 had no evidence of local recurrence but had evidence of distant disease and 7 had died of the disease. Conclusions: Radio frequency ablation is feasible and safe in highly selected patients with metastatic renal cell carcinoma, resulting in durable local control as part of multimodality management and achieving renal preservation. Further investigation is required to define the role of radio frequency ablation in this patient population. References 1 : The changing natural history of renal cell carcinoma. J Urol2001; 166: 1611. Link, Google Scholar 2 : Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res2004; 10: 6335S. Google Scholar 3 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001; 345: 1655. Crossref, Medline, Google Scholar 4 : Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001; 358: 966. Crossref, Medline, Google Scholar 5 : Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004; 171: 1071. Link, Google Scholar 6 : The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol2006; 176: 1990. Link, Google Scholar 7 : Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer2007; 110: 2428. Google Scholar 8 : Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology2008; 72: 1090. Google Scholar 9 : Radiofrequency ablation of renal cell carcinoma: part 1, indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol2005; 185: 64. Google Scholar 10 : Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol2007; 189: 429. Google Scholar 11 : General anesthesia and contrast-enhanced computed tomography to optimize renal percutaneous radiofrequency ablation: multi-institutional intermediate-term results. J Endourol2009; 23: 1099. Google Scholar 12 : Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol2003; 170: 178. Link, Google Scholar 13 : Is radiofrequency ablation safe for solitary kidneys?. Urology2007; 69: 819. Google Scholar 14 : Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol2006; 176: 1973. Link, Google Scholar 15 : A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med1999; 130: 461. Google Scholar 16 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007; 356: 2271. Google Scholar 17 : Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol2009; 10: 757. Google Scholar 18 : Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol2009; 6: 375. Google Scholar 19 : Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol1992; 147: 24. Link, Google Scholar 20 : Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol1990; 144: 614. Link, Google Scholar 21 : The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol2007; 177: 1978. Link, Google Scholar 22 : VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist2005; 10: 191. Google Scholar 23 : Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment. Int J Urol2001; 8: 275. Google Scholar 24 : Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol2001; 158: 735. Google Scholar 25 : In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res2004; 64: 4024. Google Scholar 26 : Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res2006; 66: 1139. Google Scholar 27 : Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology2009; 251: 58. Google Scholar 28 : RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol2008; 32: 481. Google Scholar 29 : Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother2008; 31: 271. Google Scholar 30 Matin SF, Sharma P, Gill IS et al: Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183: 333. Google Scholar © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 184Issue 5November 2010Page: 1882-1887 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.Keywordsneoplasm metastasiscatheter ablationkidneycarcinomarenal cellmortalityAcknowledgmentsBryan Tutt, Department of Scientific Publications, University of Texas M. D. Anderson Cancer Center reviewed the manuscript.MetricsAuthor Information Jose A. Karam Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Kamran Ahrar Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Christopher G. Wood Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Eric Jonasch Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with Pfizer, Novartis, Bayer Onyx, Wyeth and Genentech. More articles by this author Raghunandan Vikram Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Claudio Romero Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Nizar Tannir Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Surena F. Matin Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2059094471 created "2016-06-24" @default.
• W2059094471 creator A5002650017 @default.
• W2059094471 creator A5007689146 @default.
• W2059094471 creator A5017537551 @default.
• W2059094471 creator A5027401997 @default.
• W2059094471 creator A5040751011 @default.
• W2059094471 creator A5058115259 @default.
• W2059094471 creator A5073556374 @default.
• W2059094471 creator A5085172191 @default.
• W2059094471 date "2010-11-01" @default.
• W2059094471 modified "2023-10-18" @default.
• W2059094471 title "Radio Frequency Ablation of Renal Tumors in Patients With Metastatic Renal Cell Carcinoma" @default.
• W2059094471 cites W1967164197 @default.
• W2059094471 cites W1970941392 @default.
• W2059094471 cites W1983501452 @default.
• W2059094471 cites W1991069920 @default.
• W2059094471 cites W2003891025 @default.
• W2059094471 cites W2005429524 @default.
• W2059094471 cites W2007387607 @default.
• W2059094471 cites W2011612190 @default.
• W2059094471 cites W2014636539 @default.
• W2059094471 cites W2021256410 @default.
• W2059094471 cites W2036343195 @default.
• W2059094471 cites W2055864845 @default.
• W2059094471 cites W2057429666 @default.
• W2059094471 cites W2061808718 @default.
• W2059094471 cites W2075823660 @default.
• W2059094471 cites W2104661991 @default.
• W2059094471 cites W2105937199 @default.
• W2059094471 cites W2107438504 @default.
• W2059094471 cites W2111616718 @default.
• W2059094471 cites W2116661424 @default.
• W2059094471 cites W2122924344 @default.
• W2059094471 cites W2142583773 @default.
• W2059094471 cites W2144390074 @default.
• W2059094471 cites W2153867442 @default.
• W2059094471 cites W2157584612 @default.
• W2059094471 cites W2160120519 @default.
• W2059094471 cites W2169808388 @default.
• W2059094471 cites W2399984187 @default.
• W2059094471 cites W2409576273 @default.
• W2059094471 doi "https://doi.org/10.1016/j.juro.2010.06.109" @default.
• W2059094471 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4777338" @default.
• W2059094471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20846689" @default.
• W2059094471 hasPublicationYear "2010" @default.
• W2059094471 type Work @default.
• W2059094471 sameAs 2059094471 @default.
• W2059094471 citedByCount "5" @default.
• W2059094471 countsByYear W20590944712012 @default.
• W2059094471 countsByYear W20590944712013 @default.
• W2059094471 countsByYear W20590944712015 @default.
• W2059094471 countsByYear W20590944712020 @default.
• W2059094471 crossrefType "journal-article" @default.
• W2059094471 hasAuthorship W2059094471A5002650017 @default.
• W2059094471 hasAuthorship W2059094471A5007689146 @default.
• W2059094471 hasAuthorship W2059094471A5017537551 @default.
• W2059094471 hasAuthorship W2059094471A5027401997 @default.
• W2059094471 hasAuthorship W2059094471A5040751011 @default.
• W2059094471 hasAuthorship W2059094471A5058115259 @default.
• W2059094471 hasAuthorship W2059094471A5073556374 @default.
• W2059094471 hasAuthorship W2059094471A5085172191 @default.
• W2059094471 hasBestOaLocation W20590944712 @default.
• W2059094471 hasConcept C126322002 @default.
• W2059094471 hasConcept C126838900 @default.
• W2059094471 hasConcept C126894567 @default.
• W2059094471 hasConcept C143998085 @default.
• W2059094471 hasConcept C2777472916 @default.
• W2059094471 hasConcept C2778902805 @default.
• W2059094471 hasConcept C2780091579 @default.
• W2059094471 hasConcept C2780227381 @default.
• W2059094471 hasConcept C2992838919 @default.
• W2059094471 hasConcept C2993968704 @default.
• W2059094471 hasConcept C71924100 @default.
• W2059094471 hasConceptScore W2059094471C126322002 @default.
• W2059094471 hasConceptScore W2059094471C126838900 @default.
• W2059094471 hasConceptScore W2059094471C126894567 @default.
• W2059094471 hasConceptScore W2059094471C143998085 @default.
• W2059094471 hasConceptScore W2059094471C2777472916 @default.
• W2059094471 hasConceptScore W2059094471C2778902805 @default.
• W2059094471 hasConceptScore W2059094471C2780091579 @default.
• W2059094471 hasConceptScore W2059094471C2780227381 @default.
• W2059094471 hasConceptScore W2059094471C2992838919 @default.
• W2059094471 hasConceptScore W2059094471C2993968704 @default.
• W2059094471 hasConceptScore W2059094471C71924100 @default.
• W2059094471 hasIssue "5" @default.
• W2059094471 hasLocation W20590944711 @default.
• W2059094471 hasLocation W20590944712 @default.
• W2059094471 hasLocation W20590944713 @default.
• W2059094471 hasLocation W20590944714 @default.
• W2059094471 hasOpenAccess W2059094471 @default.
• W2059094471 hasPrimaryLocation W20590944711 @default.
• W2059094471 hasRelatedWork W1551012377 @default.
• W2059094471 hasRelatedWork W1995302647 @default.
• W2059094471 hasRelatedWork W2042307088 @default.
• W2059094471 hasRelatedWork W2115453934 @default.
• W2059094471 hasRelatedWork W2138740846 @default.
• W2059094471 hasRelatedWork W2258908941 @default.

• next